ADAMTS13 Antibody
Use
Measurement of ADAMTS13 antibody level
Special Instructions
Not provided.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the FDA. Severe deficiency (<10% activity) is specific to hereditary or acquired TTP but does not exclude a clinical diagnosis if levels are greater than 10%. Other conditions may show normal or mild to moderate deficiency of ADAMTS13 activity, including hemolytic uremic syndromes and other thrombotic microangiopathies.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 40824-5 - vWF Cp Inhib PPP-aCnc
- 40824-5 - vWF Cp Inhib PPP-aCnc
Result Turnaround Time
3-9 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
0.5 mL
Minimum Volume
Not provided
Container
Blue-top (sodium citrate) tube
Collection Instructions
Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate. The sample should be mixed by gentle inversion at least six times and centrifuged promptly. Plasma must be transferred to a Labcorp transpak purple tube with screw cap and frozen immediately.
Storage Instructions
Freeze.
Causes for Rejection
Nonfrozen sample received; noncitrate plasma received; sample left on cells
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unstable |
| Refrigerated | Unstable |
| Frozen | 14 days |
Other tests from different labs that may be relevant